SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-037838
Filing Date
2020-03-24
Accepted
2020-03-24 17:23:14
Documents
2
Period of Report
2020-03-19
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2013596d1_8k.htm 8-K 40995
2 EXHIBIT 3.1 tm2013596d1_ex3-1.htm EX-3.1 9907
  Complete submission text file 0001104659-20-037838.txt   52556
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 20739274
SIC: 2836 Biological Products, (No Diagnostic Substances)